Additional Paid in Capital of Travere Therapeutics, Inc. from 28 Feb 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Travere Therapeutics, Inc. quarterly Additional Paid in Capital in USD history and change rate from 28 Feb 2011 to 31 Dec 2025.
  • Travere Therapeutics, Inc. Additional Paid in Capital for the quarter ending 31 Dec 2025 was $1,588,721,000, a 5.5% increase year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Travere Therapeutics, Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,588,721,000 +$82,406,000 +5.5% 31 Dec 2025 10-K 19 Feb 2026 2025 FY
Q3 2025 $1,550,051,000 +$192,594,000 +14% 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $1,534,698,000 +$185,833,000 +14% 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $1,522,050,000 +$184,412,000 +14% 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $1,506,315,000 +$178,434,000 +13% 31 Dec 2024 10-K 19 Feb 2026 2025 FY
Q3 2024 $1,357,457,000 +$38,596,000 +2.9% 30 Sep 2024 10-Q 31 Oct 2024 2024 Q3
Q2 2024 $1,348,865,000 +$42,348,000 +3.2% 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $1,337,638,000 +$45,775,000 +3.5% 31 Mar 2024 10-Q 06 May 2024 2024 Q1
Q4 2023 $1,327,881,000 +$267,906,000 +25% 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q3 2023 $1,318,861,000 +$270,094,000 +26% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $1,306,517,000 +$269,984,000 +26% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $1,291,863,000 +$270,321,000 +26% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $1,059,975,000 -$8,659,000 -0.81% 31 Dec 2022 10-K 20 Feb 2024 2023 FY
Q3 2022 $1,048,767,000 30 Sep 2022 10-Q 27 Oct 2022 2022 Q3
Q2 2022 $1,036,533,000 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $1,021,542,000 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $1,068,634,000 +$270,649,000 +34% 31 Dec 2021 10-K 23 Feb 2023 2022 FY
Q4 2020 $797,985,000 +$161,075,000 +25% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q4 2019 $636,910,000 +$47,115,000 +8% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q4 2018 $589,795,000 +$117,995,000 +25% 31 Dec 2018 10-K 24 Feb 2020 2019 FY
Q4 2017 $471,800,000 +$50,491,000 +12% 31 Dec 2017 10-K 26 Feb 2019 2018 FY
Q4 2016 $421,309,000 +$55,507,000 +15% 31 Dec 2016 10-K 06 Jul 2018 2017 FY
Q4 2015 $365,802,000 +$224,951,000 +160% 31 Dec 2015 10-K 01 Mar 2017 2016 FY
Q4 2014 $140,851,000 +$91,215,498 +184% 31 Dec 2014 10-K 26 Feb 2016 2015 FY
Q2 2014 $133,448,275 +$98,503,358 +282% 30 Jun 2014 10-Q 14 Aug 2014 2014 Q2
Q1 2014 $105,369,174 +$70,597,031 +203% 31 Mar 2014 10-Q 15 May 2014 2014 Q1
Q4 2013 $49,635,502 +$19,432,100 +64% 31 Dec 2013 10-K 11 Mar 2015 2014 FY
Q3 2013 $46,219,593 +$46,140,604 30 Sep 2013 10-Q/A 09 Jul 2015 2013 Q3
Q2 2013 $34,944,917 +$34,868,928 30 Jun 2013 10-Q 16 Sep 2013 2013 Q2
Q1 2013 $34,772,143 +$34,699,154 31 Mar 2013 10-Q/A 16 Sep 2013 2013 Q1
Q4 2012 $30,203,402 +$27,436,835 +992% 31 Dec 2012 10-Q/A 09 Jul 2015 2013 Q3
Q3 2012 $78,989* 31 Aug 2012 10-Q 10 Oct 2012 2012 Q2
Q2 2012 $75,989* 31 May 2012 10-Q 08 Aug 2012 2012 Q1
Q1 2012 $72,989* +$12,085 29 Feb 2012 10-Q 06 Mar 2013 2012 Q3
Q4 2011 $2,766,567 31 Dec 2011 10-K/A 16 Sep 2013 2012 FY
Q1 2011 $60,904* 28 Feb 2011 10-Q/A 06 Jun 2012 2011 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.